Type 2 diabetes in neuroendocrine tumors: are biguanides and statins part of the solution?

Conclusion: Given the demonstrated clinical safety of these drugs, our results invite to further explore their potential therapeutic role for the treatment of NET patients.
Precis: Clinical/molecular changes in patients with T2DM and NETs reversed in metformin treated patients. Biguanides/statins altered aggressiveness features (proliferation, apoptosis, etc.) in NET cells.
PMID: 30265346 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - September 27, 2018 Category: Endocrinology Authors: Herrera-Martínez AD, Pedraza-Arevalo S, L-López F, Gahete MD, Gálvez-Moreno MA, Castaño JP, Luque RM Tags: J Clin Endocrinol Metab Source Type: research